Granules India targets peptide CDMO profitability, plans Vizag facility
The company reported Q1FY27 profit after tax up 60% to ₹1,800 million and cut net debt to ₹1,012 million, a 0.07x debt-to-EBITDA ratio.
TR
By Tom Reyes · Markets Editor
Sep 13 16:10 ETSource: scanx.trade
The wire
- 01Granules India said Q1FY27 revenue rose 22% to ₹14,768 million and PAT rose 60% to ₹1,800 million, and set a target to turn its peptide CDMO unit PAT positive this fiscal year.
- 02The company earmarked ₹100–200 crore of capex for a new peptide facility in Vizag, adding to contract manufacturing capacity that peptide developers depend on.
- 03Guidance and targets are company statements; timing of the Vizag build and the CDMO unit's path to profitability were not detailed.
From the source
Read at scanx.tradeGranules India turns debt-free in Q1FY27, sets peptide CDMO targets
Granules India delivered robust Q1FY27 results with PAT rising 60% to ₹1,800 Mn and revenue growing 22% to ₹14,768 Mn. The company significantly reduced net debt to ₹1,012 Mn, achieving a debt-to-EBITDA ratio of 0.07x. Key strategic updates include the scaling of complex generics to 50% of FD revenue, a target to turn the peptide CDMO unit PAT positive this fiscal year, and planned capex of ₹100-2